Abstract 81P
Background
Significant unmet needs exist for patients with mNSq NSCLC who experience disease progression after treatment with PCT and an ICI. Docetaxel (DOC)-based regimens are commonly used to treat such patients; however, data on the characteristics of and outcomes for those receiving these therapies in the real world are lacking. The objective of this study was to provide a benchmark for survival with present standard-of-care therapies by conducting a retrospective cohort study of real-world patients treated with DOC or DOC plus ramucirumab (DOC+RAM) in the US.
Methods
The study utilized data from US patients included in the ConcertAI Patient 360 NSCLC database who initiated first-line treatment between 01-Jul-2016 and 31-Dec-2020. Patients who had mNSq NSCLC, an Eastern Cooperative Oncology Group performance status of 0 or 1, and received DOC or DOC+RAM following disease progression after PCT and an ICI (in combination or separately) were eligible. Patients’ demographics and clinical characteristics as well as outcomes (real-world overall survival [OS], progression-free survival [PFS], time to treatment discontinuation [TTD], and time to next treatment [TTNT]) were analyzed.
Results
For patients receiving DOC (N=41; mean age: 65 years) or DOC+RAM (N=87; mean age: 64 years), median OS was 6.0 months (95% confidence interval [CI]: 4.8, 11.6) and 5.9 months (95% CI: 4.2, 11.6), respectively. Median PFS was 2.9 months (95% CI: 1.9, 4.6) for DOC and 2.7 months (95% CI: 2.3, 4.6) for DOC+RAM. Median TTD and TTNT were 2.1 months (95% CI: 1.4, 3.4) and 7.4 months (95% CI: 5.7, not estimable [NE]) for DOC and 1.5 months (95% CI: 1.4, 2.1) and 15.2 months (95% CI: 12.3, NE) for DOC+RAM, respectively. Estimates for TTNT should be considered with caution, given that a large number of patients were censored because of death or end of follow-up.
Conclusions
This study highlights the poor prognosis for real-world mNSq NSCLC patients who experience disease progression after PCT and ICI. The results can be used to help evaluate novel therapies in this population.
Editorial acknowledgement
Hriticka Choudhurry and Pranshu Roy from Sanofi provided medical writing support.
Legal entity responsible for the study
Sanofi.
Funding
Sanofi.
Disclosure
M.A. Bittoni: Financial Interests, Institutional, Speaker, Consultant, Advisor, consultancy services: Sanofi. S. Keeping, J.E. Park, A.T.H. Nguyen, K. Toor: Financial Interests, Institutional, Full or part-time Employment: PRECISIONheor; Professional service fees for conducting this research: Sanofi. D.P. Carbone: Financial Interests, Institutional, Speaker, Consultant, Advisor, consultancy services Sanofi. N. Petruski-Ivleva, A.K. Vadanahalli Shankar, G. Konidaris: Financial Interests, Institutional, Full or part-time Employment: Sanofi; Financial Interests, Institutional, Stocks/Shares: Sanofi.
Resources from the same session
157TiP - Krascendo-170 Lung: a phase Ib/II study of divarasib + pembrolizumab _ platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)
Presenter: Ferdinandos Skoulidis
Session: Poster Display
159TiP - Two Phase 1 Studies Assessing the Safety and Efficacy of the Small Molecule Oral PD-L1 Inhibitor INCB099280 in Combination with Adagrasib (INCB 99280-204 [Study 204]) or Ipilimumab (INCB 99280-205 [Study 205]) in Adults with Advanced Solid Tumors
Presenter: David Berz
Session: Poster Display
160TiP - Safety and Antitumor Activity of GEN1042 in Combination with Pembrolizumab _ Chemotherapy in Solid Tumors: Phase 2b Dose-Expansion Trial in Progress
Presenter: Ignacio Melero
Session: Poster Display
164P - Disentangling the Joint and Distinct Immunomodulation and Vulnerability Between KEAP1/NFE2L2 and SMARCA4 Alterations in Lung Adenocarcinoma
Presenter: Anlin Li
Session: Poster Display
165P - Immunosuppressive F13A1+ Mo/M_ in the tumor microenvironment as a hallmark for multiple primary lung cancers
Presenter: Jiahao Qu
Session: Poster Display
166P - Three-dimensional (3D) Innervation of Mouse Lungs and Airways in a Lung Metastatic Tumor Model
Presenter: Yan Zhou
Session: Poster Display
167P - Lurbinectedin, a DNA minor groove inhibitor launches a multimodal immune response through activation of the cytosolic DNA-Sensing cGAS-STING pathway.
Presenter: Triparna Sen
Session: Poster Display
168P - Effect of sequence treatment of chemotherapy plus radiotherapy activates innate immunity in SCLC
Presenter: CATERINA DE ROSA
Session: Poster Display
169P - High-dimensional analysis of tumor infiltrating immune cells reveals major differences in the tumor immune microenvironments of pleural mesothelioma and lung cancer
Presenter: Angelica Rigutto
Session: Poster Display